Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

NCT01900665 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2129

Enrollment

INDUSTRY

Sponsor class

Stopped Solanezumab did not meet the study's primary endpoint.

Conditions

Alzheimer's Disease

Interventions

DRUG: Solanezumab
DRUG: Placebo

Sponsor

Eli Lilly and Company